Literature DB >> 22815132

Deciphering the role of malin in the lafora progressive myoclonus epilepsy.

Carlos Romá-Mateo1, Pascual Sanz, Matthew S Gentry.   

Abstract

Lafora disease (LD) is a fatal, autosomal recessive neurodegenerative disorder that results in progressive myoclonus epilepsy. A hallmark of LD is the accumulation of insoluble, aberrant glycogen-like structures called Lafora bodies. LD is caused by mutations in the gene encoding the E3 ubiquitin ligase malin or the glucan phosphatase laforin. Although LD was first described in 1911, its symptoms are still lacking a consistent molecular explanation and, consequently, a cure is far from being achieved. Some data suggest that malin forms a functional complex with laforin. This complex promotes the ubiquitination of proteins involved in glycogen metabolism and misregulation of pathways involved in this process results in Lafora body formation. In addition, recent results obtained from both cell culture and LD mouse models have highlighted a role of the laforin-malin complex in the regulation of endoplasmic reticulum-stress and protein clearance pathways. These results suggest that LD should be considered as a novel member of the group of protein clearance diseases such as Parkinson's, Huntington's, or Alzheimer's, in addition to being a glycogen metabolism disease. Herein, we review the latest results concerning the role of malin in LD and attempt to decipher its function. © 2012 IUBMB IUBMB Life, 64(10): 801-808, 2012.
Copyright © 2012 International Union of Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22815132      PMCID: PMC3458166          DOI: 10.1002/iub.1072

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  52 in total

1.  Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.

Authors:  Hannes Lohi; Leonarda Ianzano; Xiao-Chu Zhao; Elayne M Chan; Julie Turnbull; Stephen W Scherer; Cameron A Ackerley; Berge A Minassian
Journal:  Hum Mol Genet       Date:  2005-08-22       Impact factor: 6.150

2.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.

Authors:  Matthew S Gentry; Carolyn A Worby; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-01       Impact factor: 11.205

3.  PTG, a protein phosphatase 1-binding protein with a role in glycogen metabolism.

Authors:  J A Printen; M J Brady; A R Saltiel
Journal:  Science       Date:  1997-03-07       Impact factor: 47.728

4.  Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases.

Authors:  S Yokoi; J Austin; F Witmer; M Sakai
Journal:  Arch Neurol       Date:  1968-07

5.  Lafora disease due to EPM2B mutations: a clinical and genetic study.

Authors:  C Gómez-Abad; P Gómez-Garre; E Gutiérrez-Delicado; S Saygi; R Michelucci; C A Tassinari; S Rodríguez de Córdoba; J M Serratosa
Journal:  Neurology       Date:  2005-03-22       Impact factor: 9.910

6.  Role of protein targeting to glycogen (PTG) in the regulation of protein phosphatase-1 activity.

Authors:  M J Brady; J A Printen; C C Mastick; A R Saltiel
Journal:  J Biol Chem       Date:  1997-08-08       Impact factor: 5.157

7.  Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation.

Authors:  Maria Elena Fernández-Sánchez; Olga Criado-García; Karen E Heath; Belén García-Fojeda; Iria Medraño-Fernández; Pilar Gomez-Garre; Pascual Sanz; José María Serratosa; Santiago Rodríguez de Córdoba
Journal:  Hum Mol Genet       Date:  2003-10-07       Impact factor: 6.150

8.  Late-onset and slow-progressing Lafora disease in four siblings with EPM2B mutation.

Authors:  Betul Baykan; Pasquale Striano; Stefania Gianotti; Nerses Bebek; Elena Gennaro; Candan Gurses; Federico Zara
Journal:  Epilepsia       Date:  2005-10       Impact factor: 5.864

9.  Mutations in NHLRC1 cause progressive myoclonus epilepsy.

Authors:  Elayne M Chan; Edwin J Young; Leonarda Ianzano; Iulia Munteanu; Xiaochu Zhao; Constantine C Christopoulos; Giuliano Avanzini; Maurizio Elia; Cameron A Ackerley; Nebojsa J Jovic; Saeed Bohlega; Eva Andermann; Guy A Rouleau; Antonio V Delgado-Escueta; Berge A Minassian; Stephen W Scherer
Journal:  Nat Genet       Date:  2003-09-07       Impact factor: 38.330

10.  The phosphatase laforin crosses evolutionary boundaries and links carbohydrate metabolism to neuronal disease.

Authors:  Matthew S Gentry; Robert H Dowen; Carolyn A Worby; Seema Mattoo; Joseph R Ecker; Jack E Dixon
Journal:  J Cell Biol       Date:  2007-07-23       Impact factor: 10.539

View more
  11 in total

Review 1.  Lafora disease offers a unique window into neuronal glycogen metabolism.

Authors:  Matthew S Gentry; Joan J Guinovart; Berge A Minassian; Peter J Roach; Jose M Serratosa
Journal:  J Biol Chem       Date:  2018-02-26       Impact factor: 5.157

2.  Quantitative and functional interrogation of parent-of-origin allelic expression biases in the brain.

Authors:  Julio D Perez; Nimrod D Rubinstein; Daniel E Fernandez; Stephen W Santoro; Leigh A Needleman; Olivia Ho-Shing; John J Choi; Mariela Zirlinger; Shau-Kwaun Chen; Jun S Liu; Catherine Dulac
Journal:  Elife       Date:  2015-07-03       Impact factor: 8.140

Review 3.  Biochemical and clinical aspects of glycogen storage diseases.

Authors:  Sara S Ellingwood; Alan Cheng
Journal:  J Endocrinol       Date:  2018-06-06       Impact factor: 4.286

Review 4.  Autophagy and neurodegeneration.

Authors:  Rebecca A Frake; Thomas Ricketts; Fiona M Menzies; David C Rubinsztein
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

5.  Homeostasis of the astrocytic glutamate transporter GLT-1 is altered in mouse models of Lafora disease.

Authors:  Carmen Muñoz-Ballester; Arnaud Berthier; Rosa Viana; Pascual Sanz
Journal:  Biochim Biophys Acta       Date:  2016-03-11

Review 6.  Antibody-Mediated Enzyme Therapeutics and Applications in Glycogen Storage Diseases.

Authors:  Zhengqiu Zhou; Grant L Austin; Robert Shaffer; Dustin D Armstrong; Matthew S Gentry
Journal:  Trends Mol Med       Date:  2019-09-12       Impact factor: 11.951

7.  Nuclear Glycogenolysis Modulates Histone Acetylation in Human Non-Small Cell Lung Cancers.

Authors:  Ramon C Sun; Vikas V Dukhande; Zhengqiu Zhou; Lyndsay E A Young; Shane Emanuelle; Christine Fillmore Brainson; Matthew S Gentry
Journal:  Cell Metab       Date:  2019-09-12       Impact factor: 27.287

8.  Generation and characterization of a laforin nanobody inhibitor.

Authors:  Zoe R Simmons; Savita Sharma; Jeremiah Wayne; Sheng Li; Craig W Vander Kooi; Matthew S Gentry
Journal:  Clin Biochem       Date:  2021-04-05       Impact factor: 3.625

Review 9.  Lafora Disease: A Ubiquitination-Related Pathology.

Authors:  Maria Adelaida García-Gimeno; Erwin Knecht; Pascual Sanz
Journal:  Cells       Date:  2018-07-26       Impact factor: 6.600

10.  Dimerization of the glucan phosphatase laforin requires the participation of cysteine 329.

Authors:  Pablo Sánchez-Martín; Madushi Raththagala; Travis M Bridges; Satrio Husodo; Matthew S Gentry; Pascual Sanz; Carlos Romá-Mateo
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.